Critical Appraisal of Extended Treatment Studies in Attention-Deficit Hyperactivity Disorder
Dear Editor:
Russell Schachar and colleagues' excellent review (1) offers a sobering and necessary balance that illustrates the current limitations of our knowledge regarding treatment effects in attention-deficit hyperactivity disorder (ADHD). With regard to the combination of pharmacologic and nonpharmacologic treatment approaches, it is instructive to note that the literature does not address an important practical issue for children responding to short-term stimulants in the classroom. We know that most treatment studies have found positive benefit for short-acting stimulants, even though these medications give a benefit for only 90 minutes, approximately. Why these short-acting medications work as well as they do throughout the school day, given their short duration of action, is an important and relatively unexplored question.
A recent article on impulse disorders casts light on this question (2) . In it, Strayhorn makes the point that one aspect of working with impulse disorders concerns facilitating the development of "a positive momentum." Perhaps this is an important clue as to why the short-acting medications work as well as they do. In theory, the longer-acting stimulants provide better coverage throughout the school day; however, many children do receive good benefit from short-acting preparations-a seeming paradox. This suggests that the sustained action of these short-acting medications might be explained in terms of the development of positive momentum. If children with ADHD "get on track" for 90 minutes at the beginning of the morning and afternoon school, their positive momentum may carry them along for the remaining time. If children are more able to achieve success in the class, albeit for a short period, their self-cognitions are more likely to be positive than negative. Perhaps this is the underlying mechanism behind the sustained benefit of short-acting medications beyond their pharmacologically effective time window. If so, facilitating positive momentum with cognitive and behavioural techniques begins to make more sense. The interaction wherein the pharmacologic effects of a short-acting stimulant allow the teacher to help the child get on a positive track may be a fruitful source of further research investigating how teachers can help children with ADHD enter the learning group.
Schachar's article notes that currently available randomized treatment studies have some significant limitations regarding the wide array of outcomes that are important to measure for children and adolescents with this common disorder. An important and underexplored outcome is related to public health-driving safety and ADHD. Recent research emphasizes the increased risk of dangerous driving behaviour in young drivers with ADHD and other impulse disorders (3) . Ongoing research in this very important area of impulsivity and dangerous driving raises the possibility of identifying highrisk groups early and developing early preventive intervention strategies for an underrecognized public health issue.
Gabapentin-Induced Paradoxical Exacerbation of Psychosis in a Patient With Schizophrenia
Gabapentin is an anticonvulsant that is increasingly prescribed to patients with schizophrenia (1). Uses of anticonvulsants in this population have traditionally included antipsychotic augmentation and control of aggression and impulsivity (1) . Gabapentin is reported to have antianxiety and hypnotic effects in patients with schizophrenia (2) and panic disorder (3) . Documented behavioural side effects include hypomanic and manic mood changes, aggression, and agitation (4-6). We report a case of paradoxical worsening psychosis associated with initiation of gabapentin in a patient with schizophrenia.
Mr A, aged 23 years, was diagnosed at age 18 years with schizophrenia according to DSM-IV criteria. He has permanent, full-time employment. His medications prior to starting gabapentin included clozapine 425 mg daily, procyclidine 10 mg daily, divalproex sodium 1000 mg daily, and fluoxetine 30 mg daily. He has been maintained on divalproex sodium since his initial presentation for affective symptoms. Fluoxetine was added to alleviate medicationinduced obsessive-compulsive symptoms. No recent medication changes have been made. His baseline psychotic symptomatolgy included rare paranoid Can J Psychiatry, Vol 47, No 10, December 2002 W 975
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